600422.SS | KPC Pharmaceuticals, Inc.

Market Cap (In CNY)

12.58 Billion

Revenue (In CNY)

7.62 Billion

Net Income (In CNY)

444.67 Million

Avg. Volume

9.81 Million

Company Profile

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Mr. Sun Zhi Qiang
Employee Count: -
Website: https://www.kpc.com.cn
Ipo Date: 2000-12-06
Details: KPC Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People's Republic of China and internationally. It offers artemether, panax notoginseng, and gastrodine series drugs, as well as Chinese medicines and ethnic drugs under the Luotai, Tianxuanqing, Artemedine, Artem, and Arco brand names for treating cardio-cerebral-vascular and nervous system diseases, as well as malaria. The company also provides Dai medicines; antibiotics, chemical medicinal raw materials, chemical pharmaceutical preparations, traditional Chinese medicinal materials, biological products, biochemical drugs, and health foods; Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, and Ribavirin spray products; glycyrrhizic acid; and GLP-1, a long-acting hypoglycemic drug. It markets artemisinin antimalarials, generic drugs, and medical apparatus. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals, Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.